ERBB2 and breast cancer: As a result of OlympiAD [2] and EMBRACA [3] phase III clinical trials, PARPi were approved for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCA mt) or HER2-negative metastatic breast cancer (BC) who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic settings [4].